Form 8-K - Current report:
SEC Accession No. 0001628280-24-033629
Filing Date
2024-07-31
Accepted
2024-07-31 07:47:34
Documents
15
Period of Report
2024-07-31
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K lnth-20240731.htm   iXBRL 8-K 28097
2 EX-99.1 exhibit991q22024earningspr.htm EX-99.1 318857
6 newlantheuslogoa.jpg GRAPHIC 3408
  Complete submission text file 0001628280-24-033629.txt   498379

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT lnth-20240731.xsd EX-101.SCH 1904
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT lnth-20240731_lab.xml EX-101.LAB 21629
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT lnth-20240731_pre.xml EX-101.PRE 12510
17 EXTRACTED XBRL INSTANCE DOCUMENT lnth-20240731_htm.xml XML 2735
Mailing Address 331 TREBLE COVE ROAD NORTH BILLERICA MA 01862
Business Address 331 TREBLE COVE ROAD NORTH BILLERICA MA 01862 978 671-8001
Lantheus Holdings, Inc. (Filer) CIK: 0001521036 (see all company filings)

EIN.: 352318913 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36569 | Film No.: 241159917
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)